Literature DB >> 25701326

PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.

Jill J Severson1, Hilary S Serracino2, Valerica Mateescu2, Christopher D Raeburn3, Robert C McIntyre3, Sharon B Sams4, Bryan R Haugen5, Jena D French6.   

Abstract

Regional metastatic differentiated thyroid cancer (mDTC) provides a unique model in which to study the tumor-immune interface. These lymph node metastases persist for years, generally without progression to distant metastases. Although the immune system likely impedes disease progression, it is unsuccessful in eliminating disease. Our previous studies revealed that programmed death-1 (PD-1)(+) T cells were enriched in tumor-involved lymph nodes (TILN). Tumor-associated leukocytes and tumor cells were collected from grossly involved lymph nodes from 12 patients to further characterize the phenotype and functional potential of mDTC-associated PD-1(+) T cells. PD-1(+)CD4(+) and PD-1(+)CD8(+) T cells were enriched in 8 of 12 TILN samples. PD-1(+) T cells coexpressed Tim-3 and CD69 and failed to downregulate CD27. CD8(+) T cells, but not CD4(+) T cells, from these samples were variably deficient in their ability to produce effector cytokines when compared with control TILNs that lacked resident PD-1(+) T cells. PD-1(+)CD8(+) T cells were capable of exocytosis but lacked intracellular perforin. Surprisingly, T-cell proliferative capacity was largely maintained in all samples. Thus, although PD-1 expression by mDTC-associated CD8(+) T cells was associated with dysfunction, exhaustion was not complete. Notably, molecular markers of exhaustion did not translate to dysfunction in all samples or in CD4(+) T cells. Regulatory T cells (Treg), PD-L1, and galectin-9 were commonly found in mDTC and likely contributed to the initiation of T-cell exhaustion and disease progression. Therapies that release the effects of PD-1 and Tim-3 and reduce the suppressive effects of Tregs may encourage tumor elimination in patients with mDTC. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25701326      PMCID: PMC4457654          DOI: 10.1158/2326-6066.CIR-14-0201

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  38 in total

1.  IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Toshiro Niki; Mitsuomi Hirashima; Anne J Novak; Thomas E Witzig; Stephen M Ansell
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

3.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Authors:  Julien Fourcade; Zhaojun Sun; Ornella Pagliano; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Daniel Olive; Vijay Kuchroo; Hassane M Zarour
Journal:  Cancer Res       Date:  2011-12-28       Impact factor: 12.701

4.  The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

Authors:  Shoba Amarnath; Courtney W Mangus; James C M Wang; Fang Wei; Alice He; Veena Kapoor; Jason E Foley; Paul R Massey; Tania C Felizardo; James L Riley; Bruce L Levine; Carl H June; Jeffrey A Medin; Daniel H Fowler
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

5.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

Authors:  Lukas Baitsch; Petra Baumgaertner; Estelle Devêvre; Sunil K Raghav; Amandine Legat; Leticia Barba; Sébastien Wieckowski; Hanifa Bouzourene; Bart Deplancke; Pedro Romero; Nathalie Rufer; Daniel E Speiser
Journal:  J Clin Invest       Date:  2011-05-09       Impact factor: 14.808

6.  Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer.

Authors:  Jena D French; Gregory R Kotnis; Sherif Said; Christopher D Raeburn; Robert C McIntyre; Joshua P Klopper; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

7.  Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

Authors:  Marieke F Fransen; Marjolein Sluijter; Hans Morreau; Ramon Arens; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

8.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.

Authors:  Yan Zhang; Shengdong Huang; Dejun Gong; Yanghua Qin; Qian Shen
Journal:  Cell Mol Immunol       Date:  2010-05-31       Impact factor: 11.530

Review 9.  Mechanism of T cell exhaustion in a chronic environment.

Authors:  Hyun-Tak Jin; Yun Hee Jeong; Hyo Jin Park; Sang-Jun Ha
Journal:  BMB Rep       Date:  2011-04       Impact factor: 4.778

10.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

View more
  33 in total

1.  Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory.

Authors:  Alexander P R Bally; Yan Tang; Joshua T Lee; Benjamin G Barwick; Ryan Martinez; Brian D Evavold; Jeremy M Boss
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

2.  The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.

Authors:  Julie Ahn; Justin A Bishop; Richard B S Roden; Clint T Allen; Simon R A Best
Journal:  Laryngoscope       Date:  2017-09-22       Impact factor: 3.325

3.  Selective Destruction of Interleukin 23-Induced Expansion of a Major Antigen-Specific γδ T-Cell Subset in Patients With Tuberculosis.

Authors:  Hongbo Shen; Jin Gu; Heping Xiao; Shanshan Liang; Enzhuo Yang; Rui Yang; Dan Huang; Crystal Chen; Feifei Wang; Ling Shen; Zheng W Chen
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

4.  Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.

Authors:  Fatma Babikr; Jiangbo Wan; Aizhang Xu; Zhaojia Wu; Shahid Ahmed; Andrew Freywald; Rajni Chibbar; Yue Wu; Michael Moser; Gary Groot; Wenjun Zhang; Bing Zhang; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2021-11-15       Impact factor: 11.530

Review 5.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

6.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

7.  CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway.

Authors:  Jinglian Tao; Dong Han; Shan Gao; Wei Zhang; Hong Yu; Pei Liu; Rong Fu; Lijuan Li; Zonghong Shao
Journal:  J Cell Mol Med       Date:  2019-11-22       Impact factor: 5.310

8.  Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.

Authors:  Jill J Bastman; Hilary S Serracino; Yuwen Zhu; Michelle R Koenig; Valerica Mateescu; Sharon B Sams; Kurtis D Davies; Christopher D Raeburn; Robert C McIntyre; Bryan R Haugen; Jena D French
Journal:  J Clin Endocrinol Metab       Date:  2016-04-05       Impact factor: 5.958

Review 9.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

10.  PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.

Authors:  Soledad Cameselle-García; Sámer Abdulkader-Sande; María Sánchez-Ares; Gemma Rodríguez-Carnero; Jesús Garcia-Gómez; Francisco Gude-Sampedro; Ihab Abdulkader-Nallib; José Manuel Cameselle-Teijeiro
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.